Cellectis Sa Stock Performance
| CLLS Stock | USD 3.99 0.07 1.72% |
On a scale of 0 to 100, Cellectis holds a performance score of 5. The firm shows a Beta (market volatility) of 0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cellectis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cellectis is expected to be smaller as well. Please check Cellectis' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Cellectis' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cellectis SA are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating essential indicators, Cellectis unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 136.7 M | |
| Total Cashflows From Investing Activities | -102.6 M |
Cellectis | Build AI portfolio with Cellectis Stock |
Cellectis Relative Risk vs. Return Landscape
If you would invest 345.00 in Cellectis SA on October 31, 2025 and sell it today you would earn a total of 54.00 from holding Cellectis SA or generate 15.65% return on investment over 90 days. Cellectis SA is currently generating 0.3709% in daily expected returns and assumes 5.1927% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Cellectis, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cellectis Target Price Odds to finish over Current Price
The tendency of Cellectis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.99 | 90 days | 3.99 | about 74.36 |
Based on a normal probability distribution, the odds of Cellectis to move above the current price in 90 days from now is about 74.36 (This Cellectis SA probability density function shows the probability of Cellectis Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Cellectis has a beta of 0.44 suggesting as returns on the market go up, Cellectis average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cellectis SA will be expected to be much smaller as well. Additionally Cellectis SA has an alpha of 0.3382, implying that it can generate a 0.34 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cellectis Price Density |
| Price |
Predictive Modules for Cellectis
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cellectis SA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cellectis Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cellectis is not an exception. The market had few large corrections towards the Cellectis' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cellectis SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cellectis within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | 0.44 | |
σ | Overall volatility | 0.55 | |
Ir | Information ratio | 0.06 |
Cellectis Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cellectis for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cellectis SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cellectis SA had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 41.51 M. Net Loss for the year was (36.7 M) with profit before overhead, payroll, taxes, and interest of 82.55 M. |
Cellectis Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cellectis Stock often depends not only on the future outlook of the current and potential Cellectis' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cellectis' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 90.6 M | |
| Cash And Short Term Investments | 260.3 M |
Cellectis Fundamentals Growth
Cellectis Stock prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Stock performance.
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0447 | |||
| Profit Margin | (0.43) % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 314.85 M | |||
| Shares Outstanding | 72.33 M | |||
| Price To Earning | (14.84) X | |||
| Price To Book | 4.05 X | |||
| Price To Sales | 5.02 X | |||
| Revenue | 41.51 M | |||
| EBITDA | (9.46 M) | |||
| Cash And Equivalents | 153.13 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 91.46 M | |||
| Debt To Equity | 0.52 % | |||
| Book Value Per Share | 1.39 X | |||
| Cash Flow From Operations | 22.1 M | |||
| Earnings Per Share | (0.33) X | |||
| Total Asset | 383.54 M | |||
| Retained Earnings | (329.61 M) | |||
| Current Asset | 51 M | |||
| Current Liabilities | 26.28 M | |||
About Cellectis Performance
Assessing Cellectis' fundamental ratios provides investors with valuable insights into Cellectis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cellectis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people.Things to note about Cellectis SA performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellectis SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectis SA had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 41.51 M. Net Loss for the year was (36.7 M) with profit before overhead, payroll, taxes, and interest of 82.55 M. |
- Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
- Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectis' stock. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.